PharmaCyte Biotech, Inc.

- 27 SEP 2018
PharmaCyte Biotech Successfully Completes Comparative Analysis of Methods for Measuring Viability of Encapsulated Cells
LAGUNA HILLS, CA, September 27, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a study to determine the best assay method for the accurate determination
Read more →
- Posted in
- News
- 18 SEP 2018
PharmaCyte Biotech Successfully Completes Final Pre-Production Run of Pancreatic Cancer Product
LAGUNA HILLS, CA, September 18, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its partner, Austrianova, has successfully performed an additional pre-production “engineering
Read more →
- Posted in
- News
- 23 JUL 2018
PharmaCyte Biotech Successfully Completes Another Study on the Encapsulated Cells Used in Its Pancreatic Cancer Therapy
LAGUNA HILLS, CA, July 23, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a study on the stability after
Read more →
- Posted in
- News
- 28 JUN 2018
PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q&A Series
LAGUNA HILLS, CA, June 28, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the latest in a series of Q&A articles that PharmaCyte conducts with some of the
Read more →
- Posted in
- News
- 14 JUN 2018
PharmaCyte Biotech Successfully Completes Another FDA Required Study Necessary for Submitting Investigational New Drug Application
LAGUNA HILLS, CA, June 14, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed the comprehensive characterization of its proprietary
Read more →
- Posted in
- News
- 01 JUN 2018
PharmaCyte Biotech Receives Certificates of Analysis from Eurofins on Cells Used for Pancreatic Cancer Therapy
LAGUNA HILLS, CA, June 1, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has received Certificates of Analysis and final reports of all tests that were
Read more →
- Posted in
- News
- 30 MAY 2018
PharmaCyte Biotech CEO and CSO Interviewed About IND, Planned Clinical Trial in Pancreatic Cancer, CRO and More
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the release of a recorded interview with the company’s Chief Executive Officer, Kenneth L. Waggoner, and its Chief
Read more →
- Posted in
- News
- 16 MAY 2018
PharmaCyte Biotech Successfully Completes 29 Tests Conducted on Live Cells Used in Pancreatic Cancer Therapy
LAGUNA HILLS, CA, May 16, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the cells it will encapsulate and then use in its planned clinical trial in patients with
Read more →
- Posted in
- News
- 09 MAY 2018
PharmaCyte Biotech Successfully Completes Pore Size Studies in Cell-in-a-Box® Capsules Used in Pancreatic Cancer Therapy
LAGUNA HILLS, CA, May 9, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed the “pore size studies” on its Cell-in-a Box® capsules that are required
Read more →
- Posted in
- News
- 30 APR 2018
PharmaCyte Biotech Reports Successful Completion of Long-term Studies on Cells Used in Pancreatic Cancer Therapy
LAGUNA HILLS, CA, April 30, 2018 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the successful results of long-term studies on the type of cells that will be encapsulated using its
Read more →
- Posted in
- News

Press Releases